No

Sclerosing Agent

Treatment of small, uncomplicated varicose veins of the lower extremities

C

Arterial disease, thrombophlebitis, hypersensitivity to morrhuate sodium or any component

Sloughing and necrosis of tissue may occur following extravasation; anaphylactoid and allergic reactions have occurred; this drug should only be administered by a physician familiar with proper injection techniques; a test dose of 0.25-5 mL of a 5% injection should be given 24 hours before full-dose treatment

>10%:

Cardiovascular: Thrombosis, valvular incompetency

Dermatologic: Urticaria

Local: Burning at the site of injection, severe extravasation effects

<1%: Vascular collapse, drowsiness, headache, dizziness, nausea, vomiting, weakness, asthma, anaphylaxis

No data reported

Refrigerate

Both varicose veins and esophageal varices are treated by the thrombotic action of morrhuate sodium. By causing inflammation of the vein's intima, a thrombus is formed. Occlusion secondary to the fibrous tissue and the thrombus results in the obliteration of the vein.

Onset of action: ~5 minutes

Absorption: Most of the dose stays at the site of injection

Distribution: After treatment of esophageal varices, ~20% of dose distributes to the lungs

Adults: I.V.: 50-250 mg, repeated at 5- to 7-day intervals (50-100 mg for small veins, 150-250 mg for large veins)

For I.V. use only

No information available to require special precautions

No effects or complications reported

Avoid extravasation; use only clear solutions, solution should become clear when warmed

Injection: 50 mg/mL (30 mL)